{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T05:01:48Z","timestamp":1772600508902,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10120-025-01692-w","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T11:20:25Z","timestamp":1764847225000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-1096","authenticated-orcid":false,"given":"Ryohei","family":"Kawabata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rika","family":"Kizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Yukami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shogen","family":"Boku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Tsujinaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"1692_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1692_CR2","first-page":"220","volume":"3","author":"K Shitara","year":"2009","unstructured":"Shitara K, Muro K, Matsuo K, Ura T, Takahari D, Yokota T, et al. Chemotherapy for patients with advanced gastric cancer with performance status 2. Gastrointest Cancer Res. 2009;3:220\u20134.","journal-title":"Gastrointest Cancer Res"},{"key":"1692_CR3","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ags3.12324","volume":"4","author":"Y Kakeji","year":"2020","unstructured":"Kakeji Y, Takahashi A, Hasegawa H, Ueno H, Eguchi S, Endo I, et al. <article-title update=\u201cadded\u201d>Surgical outcomes in gastroenterological surgery in Japan: report of the National Clinical Database 2011\u20102018. Ann Gastroenterol Surg. 2020;4:250\u201374. https:\/\/doi.org\/10.1002\/ags3.12324.","journal-title":"Ann Gastroenterol Surg"},{"key":"1692_CR4","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36:2326\u201347. https:\/\/doi.org\/10.1200\/JCO.2018.78.8687.","journal-title":"J Clin Oncol"},{"key":"1692_CR5","doi-asserted-by":"publisher","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325. https:\/\/doi.org\/10.1007\/s10120-022-01331-8.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"1692_CR6","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. <article-title update=\u201cadded\u201d>Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer \u2013 a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306\u201314. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.002.","journal-title":"Eur J Cancer"},{"key":"1692_CR7","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31:4438\u201344. https:\/\/doi.org\/10.1200\/JCO.2012.48.5805.","journal-title":"J Clin Oncol"},{"key":"1692_CR8","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.ejca.2015.02.009","volume":"51","author":"K Nishikawa","year":"2015","unstructured":"Nishikawa K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, et al. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. Eur J Cancer. 2015;51:808\u201316. https:\/\/doi.org\/10.1016\/j.ejca.2015.02.009.","journal-title":"Eur J Cancer"},{"key":"1692_CR9","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/annonc\/mdv265","volume":"26","author":"K Tanabe","year":"2015","unstructured":"Tanabe K, Fujii M, Nishikawa K, Kunisaki C, Tsuji A, Matsuhashi N, et al. Phase II\/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05). Ann Oncol. 2015;26:1916\u201322. https:\/\/doi.org\/10.1093\/annonc\/mdv265.","journal-title":"Ann Oncol"},{"key":"1692_CR10","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1200\/JCO.24.01119","volume":"43","author":"D Sakai","year":"2025","unstructured":"Sakai D, Kadowaki S, Kawabata R, Hara H, Satake H, Takahashi M, et al. Randomized phase III trial of ramucirumab beyond progression plus irinotecan in patients with ramucirumab-refractory advanced gastric cancer: RINDBeRG trial. J Clin Oncol. 2025;43:2196\u2013207. https:\/\/doi.org\/10.1200\/JCO.24.01119.","journal-title":"J Clin Oncol"},{"key":"1692_CR11","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v4.00. National Cancer Institute. Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50(accessed April 12, 2025)."},{"key":"1692_CR12","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s10120-021-01271-9","volume":"25","author":"K Shitara","year":"2022","unstructured":"Shitara K, Doi T, Hosaka H, Thuss-Patience P, Santoro A, Longo F, et al. Efficacy and safety of trifluridine\/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS). Gastric Cancer. 2022;25:586\u201397. https:\/\/doi.org\/10.1007\/s10120-021-01271-9.","journal-title":"Gastric Cancer"},{"key":"1692_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s10120-018-0899-6","volume":"22","author":"K Kato","year":"2019","unstructured":"Kato K, Satoh T, Muro K, Yoshikawa T, Tamura T, Hamamoto Y, et al. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). Gastric Cancer. 2019;22:344\u201354. https:\/\/doi.org\/10.1007\/s10120-018-0899-6.","journal-title":"Gastric Cancer"},{"key":"1692_CR14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2004.08.132","volume":"22","author":"I Chau","year":"2004","unstructured":"Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2014pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol. 2004;22:2395\u2013403. https:\/\/doi.org\/10.1200\/JCO.2004.08.132.","journal-title":"J Clin Oncol"},{"key":"1692_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1634\/theoncologist.2013-0381","volume":"19","author":"D Takahari","year":"2014","unstructured":"Takahari D, Boku N, Mizusawa J, Takashima A, Yamada Y, Yoshino T, et al. Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial (JCOG9912). Oncologist. 2014;19:358\u201366. https:\/\/doi.org\/10.1634\/theoncologist.2013-0381.","journal-title":"Oncologist"},{"key":"1692_CR16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/annonc\/mdl501","volume":"18","author":"J Lee","year":"2007","unstructured":"Lee J, Lim T, Uhm JE, Park KW, Park SH, Lee SC, et al. Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma. Ann Oncol. 2007;18:886\u201391. https:\/\/doi.org\/10.1093\/annonc\/mdl501.","journal-title":"Ann Oncol"},{"key":"1692_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10120-016-0681-6","volume":"20","author":"V Fanotto","year":"2017","unstructured":"Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer. 2017;20:825\u201333. https:\/\/doi.org\/10.1007\/s10120-016-0681-6.","journal-title":"Gastric Cancer"},{"key":"1692_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.5230\/jgc.2017.17.e16","volume":"17","author":"CS Fuchs","year":"2017","unstructured":"Fuchs CS, Muro K, Tomasek J, Van Cutsem E, Cho JY, Oh SC, et al. Prognostic factor analysis of overall survival in gastric cancer from two phase III studies of second-line ramucirumab (REGARD and RAINBOW) using pooled patient data. J Gastric Cancer. 2017;17:132\u201344. https:\/\/doi.org\/10.5230\/jgc.2017.17.e16.","journal-title":"J Gastric Cancer"},{"key":"1692_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/sj.bjc.6602965","volume":"94","author":"AB Crumley","year":"2006","unstructured":"Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94:637\u201341. https:\/\/doi.org\/10.1038\/sj.bjc.6602965.","journal-title":"Br J Cancer"},{"key":"1692_CR20","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.21037\/tcr-23-1190","volume":"12","author":"T Jiang","year":"2023","unstructured":"Jiang T, Zeng Q, He J. Do alkaline phosphatases have great potential in the diagnosis, prognosis, and treatment of tumors? Transl Cancer Res. 2023;12:2932\u201345. https:\/\/doi.org\/10.21037\/tcr-23-1190.","journal-title":"Transl Cancer Res"},{"key":"1692_CR21","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10120-015-0549-1","volume":"19","author":"H Bando","year":"2016","unstructured":"Bando H, Yamada Y, Tanabe S, Nishikawa K, Gotoh M, Sugimoto N, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer. Gastric Cancer. 2016;19:919\u201326. https:\/\/doi.org\/10.1007\/s10120-015-0549-1.","journal-title":"Gastric Cancer"},{"key":"1692_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1007\/s10120-023-01423-z","volume":"26","author":"R Kawabata","year":"2023","unstructured":"Kawabata R, Chin K, Takahari D, Hosaka H, Muto O, Shindo Y, et al. Multicenter phase II study of capecitabine plus oxaliplatin in older patients with advanced gastric cancer: the Tokyo Cooperative Oncology Group TCOG GI-1601 study. Gastric Cancer. 2023;26:1020\u20139. https:\/\/doi.org\/10.1007\/s10120-023-01423-z.","journal-title":"Gastric Cancer"},{"key":"1692_CR23","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1111\/cas.14586","volume":"111","author":"M Asaka","year":"2020","unstructured":"Asaka M, Kobayashi M, Kudo T, Akino K, Asaka Y, Fujimori K, et al. Gastric cancer deaths by age group in Japan: outlook on preventive measures for elderly adults. Cancer Sci. 2020;111:3845\u201353. https:\/\/doi.org\/10.1111\/cas.14586.","journal-title":"Cancer Sci"},{"key":"1692_CR24","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","volume":"32","author":"H Wildiers","year":"2014","unstructured":"Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014;32:2595\u2013603. https:\/\/doi.org\/10.1200\/JCO.2013.54.8347.","journal-title":"J Clin Oncol"},{"key":"1692_CR25","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.23.00933","volume":"41","author":"W Dale","year":"2023","unstructured":"Dale W, Klepin HD, Williams GR, Alibhai SMH, Bergerot CD, Brintzenhofeszoc K, et al. Practical assessment and management of vulnerabilities in older patients receiving systemic cancer therapy: ASCO guideline update. J Clin Oncol. 2023;41:4293\u2013312. https:\/\/doi.org\/10.1200\/JCO.23.00933.","journal-title":"J Clin Oncol"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01692-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01692-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01692-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:59:57Z","timestamp":1770127197000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01692-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1692"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01692-w","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare the following financial interests\/personal relationships, which may be considered potential competing interests: DS reports receiving speaker\u2019s fees from Chugai Pharmaceutical Co., Ltd., and Daiichi Sankyo Co., Ltd.\/UCB Japan Co., Ltd.; and institutional research funding from Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Astellas Pharma Inc., Incyte Biosciences Japan G.K., Taiho Pharmaceutical Co., Ltd., and Eisai Co., Ltd. TSatoh reports receiving honoraria from Chugai Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Eli Lilly Japan K.K., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., Merck & Co., Inc., Astellas Pharma Inc., Taiho Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and Daiichi Sankyo Co., Ltd.; and serving in a consulting or advisory role for Bayer Yakuhin, Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Takara Bio Inc., Merck Serono Co., Ltd., and Nippon Kayaku Co., Ltd. All other authors (Ryohei Kawabata, Toshio Shimokawa, Rika Kizawa, Toru Ishiguro, Hiroki Yukami, Shogen Boku, Toshifumi Yamaguchi, Shunji Endo, Toshimasa Tsujinaka) declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national), the Japanese Clinical Trials Act, and the Helsinki Declaration of 1964 and later versions. Informed consent for the study, or an equivalent, was obtained from all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies using animal subjects performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human or animal rights"}}]}}